GlaxoSmithKline, Bristol-Myers Squibb see second quarter growth

GlaxoSmithKline reported positive second quarter results based on strong sales growth of its Seretide/Advair drug for asthma and its Avandia/Avandamet drug for diabetes.
"Our key products, led by Seretide/Advair continue to drive sales growth across all regions," said chief executive Jean-Paul Garnier.
The company posted a 7 percent rise in profits during the second quarter and also launched to new products in the U.S.– Boniva for osteoporosis and Requip for restless legs syndrome.
On Wednesday, Bristol-Myers Squibb said its second-quarter net income leaped 91 percent because of a lower tax rate and sales grew by 1.5 percent.
The company earned $1 billion, up from $527 million a year earlier. Bristol-Myers set aside $294 million more than necessary to pay taxes this year. The company also took a litigation charge of $455 million a year ago.
Revenue from its diabetes drug Glucovance dropped 74 percent to $12 million and sales of cancer drug Paraplatin sales dropped 86 percent to $33 million. Sales of AIDS drug Reyataz more than doubled to $183 million, while revenue from anti-psychotic Abilify jumped 97 percent to $240 million. Sales of anticoagulant Plavix, which is co-marketed with Sanofi-Aventis rose 26 percent to $968 million.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions